Key Developments: Cytosorbents Corp (CTSO.PK)
0.12USD
20 May 2013
$0.00 (-3.23%)
$0.12
$0.11
$0.12
$0.11
725,028
336,895
$0.17
$0.09
Latest Key Developments (Source: Significant Developments)
CytoSorbents Corp Appoints CFO
CytoSorbents Corp announced the appointment of Kathleen P. Bloch, MBA, CPA, as its Chief Financial Officer (CFO), effective May 29, 2013. Full Article
CytoSorbents Corp Secures Additional Phase I Option On US Army SBIR Trauma Contract
CytoSorbents Corp announced the award of an additional Phase I Option SBIR (Small Business Innovation Research) contract by the US Army Medical Research and Materiel Command, valued at $50,000 over a 2 month period. The Phase I Option is intended to fund program-related interim research and development in advance of finalizing contract negotiations on the previously announced $1 million Phase II SBIR award. The Phase II SBIR award will fund animal research in trauma and burn injury using the Company's proprietary CytoSorb cytokine removal technology. This work is supported by the US Army Medical Research and Materiel Command under an amendment of Contract No W81XWH-12-C-0038. Full Article
CytoSorbents Corp Appoints Interim Chief Financial Officer
CytoSorbents Corp announced the appointment of Mr. Ronald Berger as Interim Chief Financial Officer. Mr. Berger replaces Mr. Thomas Bocchino, Chief Financial Officer. The change takes effect immediately. Full Article
CytoSorbents Corp Appoints Thomas Bocchino as Chief Financial Officer
CytoSorbents Corp announced that it has appointed Thomas Bocchino as Chief Financial Officer. Full Article
DARPA Awards $3.8 Million Contract to CytoSorbents Corporation
CytoSorbents Corporation announced that the Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones. Under the terms of this contract, CytoSorbents will develop the broad-spectrum, porous polymers capable of removing cytokines, toxins and certain biowarfare agents from whole blood, with $1.5 million in funding designated for the first of five years, based upon the achievement of pre-determined milestones. Full Article
CytoSorbents Corporation Announces Departure Of CFO David Lamadrid
CytoSorbents Corporation announced the pending departure of David Lamadrid, Chief Financial Officer (CFO), effective July 11, 2012 following over 12 years of service to the Company due to personal reasons. Mr. Lamadrid started consulting with the Company's founders in 1999, joined full time as VP of Finance in 2000, and has been the Company's CFO since 2002. Upon his departure the Company is appointing Ron Berger, its current Controller, as interim CFO. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
